Toumaz Technology, the specialist in wireless persoal monitoring and signals technology, has announced that its hardware, software and sensors that are being used for large-scale data capture in the DIAdvisor clinical trial.

DIAdvisor, is an European Commission backed collaborative research project aimed at developing a personal blood glucose predictor and treatment advisor for diabetes patients.

The first year of the project involved the implementation of a large-scale data-acquisition clinical trial involving 90 patients across three sites in Europe: France, Italy and Czech Republic

DIAdvisor is a large-scale integration project aimed at the development of a prediction-based tool which uses past and easily available information to optimise the therapy of type I and developed type II diabetes.

As leaders of Workpackage 4, Toumaz Technology is responsible for the device platform development, including hardware, software and sensors and has ensured the successful and timely delivery of this device platform in the first year of the project.

The aim of the project is to develop and test technology that will allow patients to actively and accurately predict their short-term blood glucose outlook. This is enabled by analysing data retrieved from glucose measurements, insulin delivery data and specific patient parameters.

The key data, captured by tiny, non-intrusive body-worn wireless monitors including those based on Toumaz Technology’s Sensium platform, will be used to create physiological mathematical modelling, control and prediction algorithms.

Resulting analysis and prediction information will then be wirelessly transmitted to a healthcare provider advisory service, with recommended action and treatment advice presented to the patient via a handheld mobile device such as a PDA or smartphone.

The collaborative DIAdvisor project received a €7.1m EU grant in April 2008 and the large-scale four year research and development project is being coordinated by Novo Nordisk. The project is being delivered by a consortium of 13 medical, industrial and academic partners.

The DIAdvisor project consortium recently held its second General Assembly (GA2), to review progress at end of the first year of the project. The GA2 meeting was hosted by consortium members Toumaz Technology at the Institute of Biomedical Engineering at Imperial College London.

Dr Alison Burdett, director of technology for Toumaz Technology said: “The development of the DIAdvisor personal blood glucose predictor and treatment advisor has the potential to revolutionise the therapy of millions of diabetes sufferers in Europe and worldwide, minimising the occurrence of diabetic complications and reducing healthcare costs.”

Toumaz Technology Limited is a specailist in the design of ultra-low power wireless infrastructure for body monitoring solutions. Toumaz says its ultra low-power smart sensor interface and transceiver platform – the Sensium – enables non-intrusive, real-time wireless monitoring of multiple vital signs.

Professor Christofer Toumazou, chairman of Toumaz Holdings, said: "Our Sensium technology is proving core in the deployment of a commercial solution to produce a successful personal continuous predictable monitor that will help transform the lives for diabetes sufferers."



Toumaz Technology